Last reviewed · How we verify
Loop Diuretics
Loop diuretics inhibit the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing sodium and chloride reabsorption and increasing urine output.
Loop diuretics inhibit the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing sodium and chloride reabsorption and increasing urine output. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
At a glance
| Generic name | Loop Diuretics |
|---|---|
| Also known as | IV Loop Diuretics, furosemide |
| Sponsor | Policlinico Casilino ASL RMB |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the Na-K-2Cl cotransporter (NKCC2), loop diuretics prevent the reabsorption of sodium, potassium, and chloride in the thick ascending limb, the segment of the nephron responsible for the greatest proportion of electrolyte reabsorption. This leads to increased urinary excretion of sodium, chloride, water, and potassium, resulting in significant diuresis and reduction in blood volume and blood pressure. Loop diuretics are the most potent class of diuretics available.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
- Pulmonary edema
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity
- Hyperglycemia
- Hyponatremia
- Dehydration
- Hypotension
Key clinical trials
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Evaluation of the Effects of Sauna Therapy on Congestion and Loop Diuretic Use in Patients With Heart Failure With Reduced or Moderately Reduced Ejection Fraction (NA)
- Baroreflex Activation Therapy for Heart Failure (NA)
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |